Summary
Definition
History and exam
Key diagnostic factors
- previous VTE, thrombophilia, malignancy, postoperative setting, trauma, and indwelling central catheter
- chronic medical conditions, paresis, increasing age, obesity, oestrogen-containing contraceptive pills and hormone replacement therapy, varicose veins, pregnancy and up to 6 week postnatal, first-degree relative with a history of VTE, extended travel, and admission to intensive care
Risk factors
- previous VTE (deep vein thrombosis [DVT] and/or pulmonary embolism [PE])
- thrombophilia
- malignancy
- postoperative setting
- trauma
- indwelling central catheter (upper or lower extremity)
- immobility
- myeloproliferative diseases
- congestive heart failure
- chronic obstructive pulmonary disease
- inflammatory bowel disease
- neurological disease with extremity paresis
- increasing age
- obesity
- oestrogen-containing contraceptive pills, hormone replacement therapy (HRT), and androgen deprivation therapy
- history of varicose veins
- pregnancy/postnatal
- extended travel
- lower leg immobility
- first-degree relative with a history of VTE
- admission to intensive care
Diagnostic investigations
1st investigations to order
- FBC
- serum creatinine
- INR
- PTT
Investigations to consider
- serum antiplatelet factor 4 antibodies
Treatment algorithm
all at-risk patients
trauma patients
surgical patients
medical patients
Contributors
Authors
Nathalie Routhier, MD, MSc, FRCPC
Attending Physician
Assistant Professor
University of Montreal
Montreal
Canada
Disclosures
NR declares that she has no competing interests.
Vicky Tagalakis, MD, FRCPC, MSC

Associate Professor
General Internal Medicine Program Director
McGill University Division of Internal Medicine
Centre for Clinical Epidemiology of the Lady Davis Institute for Medical Research
Jewish General Hospital
Montreal
Canada
Disclosures
VT declares that she has received an investigator-initiated grant from Sanofi-Aventis. She has also received consultancy fees from and given lectures sponsored by Bristol-Myers Squibb, Pfizer, Sanofi-Aventis, and Servier. VT is an author of references cited in this topic.
Farah Zarka,
Vasculitis Clinic
Department of Medicine
Hôpital du Sacré-Coeur de Montréal
University of Montreal
Montreal
Canada
Disclosures
FZ declares that she has no competing interests.
Acknowledgements
Dr Nathalie Routhier, Dr Vicky Tagalakis, and Dr Farah Zarka would like to gratefully acknowledge Dr Vincent Bouchard-Dechêne and Dr Adi J. Klil-Drori, previous contributors to this topic.
Disclosures
VBD and AJKD declare no competing interests.
Peer reviewers
Andrew Parfitt, MBBS, FFAEM
Clinical Director
Acute Medicine
Associate Medical Director
Consultant Emergency Medicine
Guy's and St Thomas' NHS Foundation Trust
Clinical Lead and Consultant
Accident Emergency Medicine
St Thomas' Hospital
London
UK
Disclosures
AP declares that he has no competing interests.
Sudeep Shivakumar, MD
Hematologist
Thrombosis Fellow
University of Ottawa
Ottawa Health Research Institute
Ottawa
Canada
Disclosures
SS declares that he has no competing interests.
Guidelines
- American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, Sociedad Peruana de Hematología, and SVH 2022 guidelines for prevention of venous thromboembolism in surgical and medical patients and long-distance travelers in Latin America
- American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer
More GuidelinesPatient leaflets
Deep vein thrombosis
DVT and long-distance travel
More Patient leafletsLog in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer